Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Immunotherapy in mucosal melanoma: a case report and review of the literature

H. Studentova, H. Kalabova, P. Koranda, K. Chytilova, L. Kucerova, B. Melichar, D. Vrana,

. 2018 ; 9 (25) : 17971-17977. [pub] 20180403

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18024076

Background: Mucosal melanoma is a rare form of melanoma presenting variably as sores or unexplained bleeding located mainly in the head and neck region, anorectal region or female genital tract. Mucosal melanoma is usually diagnosed at an advanced stage and is characterized by an aggressive behavior. Surgery represents the mainstay of treatment for early stage melanomas, but for advanced disease there have been until recently very limited treatment options. Ipilimumab, a human monoclonal antibody directed against the cytotoxic T lymphocyte antigen 4, was the first treatment modality to demonstrate survival benefit in advanced malignant melanoma. Method: Description of a new case and review of the literature. Results: We present here a patient with mucosal melanoma with aggressive biological behavior and documented late response to ipilimumab. Conclusions: Ipilimumab represents an effective treatment option in selected patients with mucosal melanoma.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18024076
003      
CZ-PrNML
005      
20230720122540.0
007      
ta
008      
180709s2018 xxu f 000 0|engg|
009      
AR
024    7_
$a 10.18632/oncotarget.24727 $2 doi
035    __
$a (PubMed)29707161
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Studentova, Hana $u Department of Oncology, Palacký University, Faculty of Medicine and Dentistry and University Hospital, Olomouc, Czech Republic.
245    10
$a Immunotherapy in mucosal melanoma: a case report and review of the literature / $c H. Studentova, H. Kalabova, P. Koranda, K. Chytilova, L. Kucerova, B. Melichar, D. Vrana,
520    9_
$a Background: Mucosal melanoma is a rare form of melanoma presenting variably as sores or unexplained bleeding located mainly in the head and neck region, anorectal region or female genital tract. Mucosal melanoma is usually diagnosed at an advanced stage and is characterized by an aggressive behavior. Surgery represents the mainstay of treatment for early stage melanomas, but for advanced disease there have been until recently very limited treatment options. Ipilimumab, a human monoclonal antibody directed against the cytotoxic T lymphocyte antigen 4, was the first treatment modality to demonstrate survival benefit in advanced malignant melanoma. Method: Description of a new case and review of the literature. Results: We present here a patient with mucosal melanoma with aggressive biological behavior and documented late response to ipilimumab. Conclusions: Ipilimumab represents an effective treatment option in selected patients with mucosal melanoma.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kalabova, Hana $u Department of Oncology, Palacký University, Faculty of Medicine and Dentistry and University Hospital, Olomouc, Czech Republic.
700    1_
$a Koranda, Pavel $u Department of Nuclear Medicine, Palacký University, Faculty of Medicine and Dentistry and University Hospital, Olomouc, Czech Republic.
700    1_
$a Chytilová, Karin $u Department of Maxillofacial Surgery, Palacký University, Faculty of Medicine and Dentistry and University Hospital, Olomouc, Czech Republic. $7 xx0304254
700    1_
$a Kucerova, Ladislava $u Department of Pathology, Palacký University, Faculty of Medicine and Dentistry and University Hospital, Olomouc, Czech Republic.
700    1_
$a Melichar, Bohuslav $u Department of Oncology, Palacký University, Faculty of Medicine and Dentistry and University Hospital, Olomouc, Czech Republic. Institute of Molecular and Translational Medicine, Palacký University, Faculty of Medicine and Dentistry and University Hospital, Olomouc, Czech Republic.
700    1_
$a Vrana, David $u Department of Oncology, Palacký University, Faculty of Medicine and Dentistry and University Hospital, Olomouc, Czech Republic.
773    0_
$w MED00184852 $t Oncotarget $x 1949-2553 $g Roč. 9, č. 25 (2018), s. 17971-17977
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29707161 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20230720122535 $b ABA008
999    __
$a ind $b bmc $g 1316063 $s 1020994
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 9 $c 25 $d 17971-17977 $e 20180403 $i 1949-2553 $m Oncotarget $n Oncotarget $x MED00184852
LZP    __
$a Pubmed-20180709
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace